dana-farber cancer institute: guru sonpavde, md at asco gu21 (urothelial carcinoma)
Published 3 years ago • 69 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
1:44
dr. guru sonpavde on bladder cancer | dana-farber cancer institute
-
1:25
bladder cancer research: immunotherapy outcomes | dana-farber cancer institute
-
22:09
2024 asco bladder cancer highlights
-
2:22
bladder cancer advances | asco gu21
-
2:03
dana-farber cancer institute: mary-ellen taplin, md (asco gu21 prostate cancer)
-
6:41
studies: prostate cancer patients do better with surgery
-
49:28
pnh: intravascular hemolysis and extravascular hemolysis
-
11:04
bladder cancer - overview (types, pathophysiology, diagnosis, treatment)
-
6:57
dr. guru sonpavde
-
2:11
dr. mary-ellen taplin on treating prostate/gu cancers | dana-farber cancer institute
-
26:17
2022 gu asco bladder cancer highlights
-
2:01
dr. guru sonpavde, dana-farber cancer institute, usa
-
1:23
bladder cancer research at esmo 2021
-
0:46
dr. sonpavde on the need for phase 3 data with pembrolizumab or atezolizumab in bladder cancer
-
1:26
dr. sonpavde on remaining questions with immunotherapy in bladder cancer
-
0:50
dr. sonpavde on immunotherapy combination studies in urothelial carcinoma
-
1:05
dr. sonpavde on the role of durvalumab in platinum-refractory bladder cancer
-
1:23
how is prostate cancer treated? | dana-farber cancer institute
-
1:10
dr. sonpavde on the potential for neoadjuvant immunotherapy in bladder cancer
-
2:10
highlights in bladder cancer
-
12:59
vial presents: challenges in bladder cancer trials with dr. guru sonpavde